Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
NCT02875132Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Feb 2017
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in acral lentiginous melanoma (ALM), sponsored by The Chinese University of Hong Kong. Started Feb 2017; status: completed.
02
Drugs
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT02875132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02875132.